Tenderwize
Zurück zur Suche

Pharmaceutical products with the active substance Dupilumab (ATC: D11AH05)

AOK Sachsen - Anhalt·Magdeburg, Germany·Deadline Mar 30, 2028 · 582 days left·Open·Supplies
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Dupilumab (ATC: D11AH05)

50/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Warum diese Bewertung?

Chance

50 / 100

Komplexität

20 / 100

Risikofaktoren

AOK Sachsen-Anhalt may terminate the open-house contracts at any time if exclusive contracts are tendered for Dupilumab...

The notice does not guarantee any minimum quantity or sales volume; the discount agreement may result in negligible rev...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Conclusion of non-exclusive discount agreements for pharmaceutical products containing Dupilumab (ATC: D11AH05) with interested pharmaceutical companies under an open-house model.
  • All eligible companies can join at any time during the contract period (01.06.2026 – 31.05.2028) under identical conditions.
Vollständige Zusammenfassung anzeigen

This is a voluntary publication for non-exclusive discount agreements for the active substance Dupilumab (ATC: D11AH05) under an open-house model by AOK Sachsen-Anhalt. All eligible pharmaceutical companies can join at any time with standardized contract conditions. No public procurement rules apply; the publication is for transparency only. No estimated value or award criteria are provided.

Risiken

AOK Sachsen-Anhalt may terminate the open-house contracts at any time if exclusive contracts are tendered for Dupilumab...

The notice does not guarantee any minimum quantity or sales volume; the discount agreement may result in negligible rev...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Must be a pharmaceutical company or consortium of pharmaceutical companies.

Administrative

  • Must request and complete the participation documents (standardized contract and application form).
  • Submission with qualified electronic signature (eIDAS) or by postal mail.

Auftraggeber

Ort

Magdeburg, DEU

Auftraggeberprofil

Profil öffnen

Kennung

DE258393558

Tätigkeit

Health

Lose (1)

LOT-0001

Pharmaceutical products with the active substance Dupilumab (ATC: D11AH05)

Non-exclusive discount agreements for finished medicinal products containing Dupilumab under an open-house model. Contract duration up to 24 months starting from 01.06.2026 until 31.05.2028. Contracts may be terminated early if exclusive contracts are tendered.

SuppliesEU fundedElectronic submission

Ort

DEE03, Germany

Dauer

2 YEAR

Kategorie

Pharmaceutical products

Frist

Deadline Mar 30, 2028

Vergabedetails

Veröffentlichungsdatum
27 Apr 2026
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
290121-2026

Dokumente (1)

Ähnliche Ausschreibungen